Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho, Delvys Rodriguez-Abreu, Ihab Abdulkader, Josep Ramirez, Noemí Reguart, Marta Salido, Lara Pijuán, Edurne Arriola, Julián Sanz, Victoria Folgueras, Noemí Villanueva, Javier Gómez-Román, Manuel Hidalgo, Fernando López-Ríos
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Online Access:	https://doi.org/10.1371/journal.pone.0107200